Q3 2025
Ends Sep 30, 2025
Revenue
$0.0B
$0.0B to $0.0B
EPS
0.00
0.00 to 0.00
No analyst count
EPS: No analyst count
Apr 30, 05:32 PM UTC
stable/analyst-estimates
Financial Services
Live Price
Offline$18.29
+0.11% today
1Y Change
+12.73%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Payden Equity Income Fund Adviser Cl (PYVAX) is a fund with a market cap of $1.28B and listed on NASDAQ. The fund last traded around $18.29 and up 12.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include a dividend yield of 5.9%. Valuation already assumes a fairly strong business story at price/sales 139.2. Stock Foundry combines PYVAX price history, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PYVAX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PYVAX Max Drawdown
-7.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PYVAX and SPY.
EPS Consensus
0.00
Range 0.00 → 0.00
No analyst count
Revenue Outlook
$0.0B
Range $0.0B → $0.0B
No analyst count
vs prior: -0.7%Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from FMP.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.